Effects of hydrofluoroalkane formulations of ciclesonide 400 µg once daily vs fluticasone 250 µg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma
- 1 July 2004
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 58 (1) , 26-33
- https://doi.org/10.1111/j.1365-2125.2004.02108.x
Abstract
There are no data comparing the relative efficacy of hydrofluoroalkane (HFA) formulations of ciclesonide (CIC) and fluticasone propionate (FP) on airway hyper-responsiveness, in mild-to-moderate persistent asthma. We therefore elected to evaluate the comparative efficacy of HFA pressurized metered-dose inhaler formulations of CIC and FP, assessing methacholine challenge, in addition to exhaled nitric oxide, lung function, diary cards and quality of life. Nineteen mild-to-moderate asthmatic patients completed the study per protocol in randomized, double-blind, double-dummy, crossover fashion. Patients were required to stop their usual inhaled corticosteroid therapy for the duration of the study. Patients were commenced instead on salmeterol (SM) 50 microg one puff twice daily + montelukast (ML) 10 mg once daily for 2-week washout periods prior to each randomized treatment, in order to prevent dropouts. Patients received 4 weeks of either CIC 200 microg two puffs once daily (08.00 h) + CIC-placebo (PL) two puffs once daily (20.00 h) + FP-PL two puffs twice daily (08.00 h and 20.00 h), or FP 125 microg two puffs twice daily (08.00 h and 20.00 h) + CIC-PL two puffs twice daily (08.00 h and 20.00 h). SM + ML were withheld for 72 h prior to post-washout visits and CIC or FP was withheld for 24 h prior to study visits. There was no significant difference between CIC vs. FP for the primary outcome of methacholine PC20 as doubling dilution (dd) shift from respective baseline; mean difference: 0.4 dd (95% CI -0.4, 1.2). Moreover, there was no difference between treatments for the sequence of CIC first vs FP second; mean difference: 0.2 dd (95% CI -1.3, 1.7) or FP first vs CIC second; mean difference: 0.9 dd (95% CI -0.1, 1.8). There were also no differences for other secondary outcomes between treatments, either respective or irrespective of sequence, as change from baseline. There were no differences between 4 weeks of CIC 400 microg once daily and FP 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Longer-term studies are indicated to evaluate their relative efficacy on asthma exacerbations.Keywords
This publication has 25 references indexed in Scilit:
- Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatmentThorax, 2003
- A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmaticsBritish Journal of Clinical Pharmacology, 2003
- Chapters 1-3Thorax, 2003
- PrefaceJournal of Allergy and Clinical Immunology, 2002
- Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Commentary: Dosage needs systematic and criticalBMJ, 2001
- Clinical efficacy and safety of fluticasone propionate 250 $mu;g twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthmaRespiratory Medicine, 2000
- Guidelines for Methacholine and Exercise Challenge Testing—1999American Journal of Respiratory and Critical Care Medicine, 2000
- Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task ForceEuropean Respiratory Journal, 1997
- Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids.Thorax, 1996
- Standardization of Spirometry, 1994 Update. American Thoracic Society.American Journal of Respiratory and Critical Care Medicine, 1995